Royalty Pharma (FRA:RPD) Float Percentage Of Total Shares Outstanding: 98.61% (As of Jun. 30, 2026)


FRA:RPD Royalty Pharma PLC FRA:RPD
68 GF Score
Price €47.80
GF Value €31.41
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Float Percentage Of Total Shares Outstanding?

Royalty Pharma FRA:RPD +0.68% 68 Float Percentage Of Total Shares Outstanding is 98.61% as of Jun. 30, 2026. GuruFocus rates FRA:RPD with a GF Score™ of 68/100 and a GF Value™ of €31.41 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Royalty Pharma's float shares is 437.12 Mil. Royalty Pharma's total shares outstanding is 443.27 Mil. Royalty Pharma's float percentage of total shares outstanding is 98.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Royalty Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Royalty Pharma's Institutional Ownership is 59.86%.

FRA:RPD
68GF Score
Royalty Pharma PLC FRA:RPD
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Royalty Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=437.12/443.27
=98.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 98.61% mean?
Royalty Pharma (FRA:RPD) has a Float Percentage Of Total Shares Outstanding of 98.61% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Float Percentage Of Total Shares Outstanding too high?
Royalty Pharma's current Float Percentage Of Total Shares Outstanding is 98.61%. Overall, Royalty Pharma has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Float Percentage Of Total Shares Outstanding compare to ROIV and MRNA?
Royalty Pharma's Float Percentage Of Total Shares Outstanding of 98.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Float Percentage Of Total Shares Outstanding is 98.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €31.41, compared to a current price of €47.80 — trading 52.2% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 98.61%. Royalty Pharma's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Float Percentage Of Total Shares Outstanding is 98.61% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €47.80 is trading 52.2% above its estimated GF Value™ of €31.41. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

  • Float Percentage Of Total Shares Outstanding: 98.61%
  • GF Value™: €31.41 vs. price of €47.80 (52.2% above fair value)
  • GF Score™: 68/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USA
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
68GF Score

Get the complete analysis for FRA:RPD

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.80
Price
€31.41
GF Value